Metabolically Robust CYP-Eicosanoid Analogues for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing n-3 PUFA-derived CYP metabolites, such as 17,18-EEQ and 19,20-EDP, are not used as therapeutics due to limited bioavailability and chemical instability, which hinders their effectiveness in treating or preventing disorders associated with neovascularization and/or inflammation, particularly ophthalmic disorders.
Innovation Solution
Development of metabolically robust analogues of n-3 PUFA metabolites, represented by compounds of general formula (I), which include specific functional groups and linkages to enhance stability and bioavailability, for use in treating or preventing disorders associated with neovascularization and/or inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural CYP metabolites (17,18-EEQ and 19,20-EDP) are used as therapeutics, then anti-inflammatory and anti-neovascularization effects are achieved, but limited bioavailability and chemical instability prevent effective treatment
Solution Approach 1:
The patent modifies the chemical structure of natural CYP metabolites by introducing metabolically robust analogues with altered functional groups and side chains. These structural parameter changes enhance chemical stability and metabolic resistance while preserving the core epoxy group that provides anti-inflammatory and anti-neovascularization activity, thereby resolving the contradiction between therapeutic effectiveness and chemical stability
Solution Approach 2:
The invention creates composite molecular structures that combine the active epoxy group of natural metabolites with stable backbone structures and metabolically resistant side chains. This composite approach maintains the biological activity of the original metabolites while incorporating stabilizing elements that prevent degradation, thus achieving both therapeutic effectiveness and chemical stability
2Reliability
If natural CYP metabolites (17,18-EEQ and 19,20-EDP) are used as therapeutics, then anti-inflammatory and anti-neovascularization effects are achieved, but limited bioavailability prevents effective treatment
Solution Approach 1:
The patent alters key structural parameters of natural CYP metabolites by introducing metabolically robust analogues with enhanced lipophilicity, improved membrane permeability, and resistance to metabolic degradation. These parameter changes increase the quantity of active compound that reaches the target site, thereby improving bioavailability while maintaining therapeutic effectiveness
Solution Approach 2:
The invention incorporates metabolically stable structures that preemptively protect against enzymatic degradation and chemical breakdown before the compound reaches its target. This beforehand cushioning through structural design ensures that sufficient quantities of the active metabolite remain intact during circulation and distribution, overcoming the bioavailability limitations of natural metabolites
Data Source
AI summary
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of developing or preventing: (i) neovascularization and/or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and/or inflammation.